title: Dobutamine as selective beta(1)-adrenoceptor agonist in in vivo studies on human thermogenesis and lipid utilization.
abstract: The use of dobutamine as selective beta(1)-adrenoceptor agonist in in vivo studies on human thermogenesis and lipid utilization was investigated in 20 men. At 2.5, 5, and 10 microg x kg(-1) x min(-1), dobutamine induced significant increases in energy expenditure, lipid oxidation, and lipolysis. The beta(1)-adrenoceptor antagonist atenolol (bolus: 42.5 microg/kg, infusion: 1.02 microg x kg(-1) x min(-1)) blocked all dobutamine-induced effects on thermogenesis and lipid utilization. All parameters remained at levels comparable to those during saline infusion. The dose of atenolol used did not inhibit beta(2)-adrenoceptor-specific changes in energy expenditure, lipid oxidation, and lipolysis during salbutamol infusion (85 ng x kg(-1) x min(-1)). This indicates that atenolol was specific for beta(1)-adrenoceptors and did not camouflage concomitant beta(2)-adrenoceptor stimulation during dobutamine infusion. Therefore, we conclude that dobutamine can be used as a selective beta(1)-adrenoceptor agonist at dosages </=10 microg x kg(-1) x min(-1) in in vivo studies on human thermogenesis and lipid utilization.
authors.affiliation: Nutrition Toxicology and Environment Research Institute Maastricht, Department of Human Biology, Maastricht University, 6200 MD Maastricht, The Netherlands. s.schiffelers@hb.unimaas.nl
authors.forename: S L
authors.initials: SL
authors.lastname: Schiffelers
authors.forename: V J
authors.initials: VJ
authors.lastname: van Harmelen
authors.forename: H A
authors.initials: HA
authors.lastname: de Grauw
authors.forename: W H
authors.initials: WH
authors.lastname: Saris
authors.forename: M A
authors.initials: MA
authors.lastname: van Baak
mesh_terms: D000293:Adolescent; D058665:Adrenergic beta-1 Receptor Agonists; D058671:Adrenergic beta-1 Receptor Antagonists; D058666:Adrenergic beta-2 Receptor Agonists; D058672:Adrenergic beta-2 Receptor Antagonists; D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D000328:Adult; D000420:Albuterol / Q000494:pharmacology; D001262:Atenolol; D001833:Body Temperature Regulation / Q000187:drug effects*; D004280:Dobutamine; D004734:Energy Metabolism / Q000187:drug effects; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005990:Glycerol / Q000097:blood; D006801:Humans; D050356:Lipid Metabolism; D008297:Male
chemical_list: D058665:Adrenergic beta-1 Receptor Agonists; D058671:Adrenergic beta-1 Receptor Antagonists; D058666:Adrenergic beta-2 Receptor Agonists; D058672:Adrenergic beta-2 Receptor Antagonists; D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D005230:Fatty Acids, Nonesterified; D004280:Dobutamine; D001262:Atenolol; D005990:Glycerol; D000420:Albuterol